Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.32 -0.14 (-4.06%) Market Cap: 489.26 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 72/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 09:30PM GMT
Release Date Price: $8.66 (+3.71%)
Unidentified Analyst

All right. Good afternoon. I hope everybody is enjoying the conference so far. Welcome to day 1 afternoon of the JPMorgan Healthcare Conference. I'm Julia Cheng. I cover life science tools and diagnostics at JPMorgan. And it's my great pleasure to introduce you to our next company presentation today by Adaptive. So with that, I'll turn it over to Chad.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thank you, Julia. I'm Chad Robins, I'm the CEO of Adaptive Biotechnologies. I want to wish everyone a happy new year for those in the room and those listening in by webcast. Momentum in Adaptive Biotechnologies is building. We're driving revenue growth. We're advancing our pipeline, and we're managing our operating expenses with a very strong cash position.

I want to remind you today, I will be making forward-looking statements both in the presentation and in the question-and-answer session afterwards. The mission of Adaptive is and always has been to translate the genetics of T cell and B cell receptors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot